LEO Phar­ma mounts an­oth­er chal­lenge to the eczema gi­ants, bet­ting $40M cash on a drug from Chi­na

LEO Phar­ma knows it’s in for a brawl with pow­er­ful play­ers in atopic der­mati­tis. With some pos­i­tive Phase III da­ta in and reg­u­la­to­ry fil­ings on the way, the Dan­ish drug­mak­er is shelling out $40 mil­lion up­front on a new drug can­di­date that goes at both eczema and asth­ma from a dif­fer­ent an­gle.

The as­set, FB825, comes out of a col­lab­o­ra­tion be­tween One­ness Biotech in Tai­wan and Mi­cro­bio Shang­hai in Chi­na. It hits the CεmX do­main of the mem­brane bound IgE (mIgE), caus­ing a de­ple­tion of mIgE pos­i­tive B-cells and there­by low­er­ing in­flam­ma­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER